Apollomics Inc. (APLM)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20264 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Apollomics Inc.’s names, not what it holds today.
5 published
1 published
1 published
| Granted | Patent | Title | Field | Owner as printed |
|---|---|---|---|---|
| Nov 28, 2023 | 11,827,707 | Anti PD-L1 antibodies | Pharmaceuticals | Apollomics Inc. |
| Jan 24, 2023 | 11,560,429 | Anti PD-1 antibodies | Pharmaceuticals | Apollomics Inc. |
| Sep 7, 2021 | 11,111,300 | Anti PD-L1 antibodies | Pharmaceuticals | Apollomics Inc. |
| Apr 20, 2021 | 10,981,994 | Anti PD-1 antibodies | Pharmaceuticals | Apollomics Inc. |
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Jul 4, 2024 | 2024/0218453 | DIAGNOSTIC AND TREATMENT OF CANCER USING C-MET INHIBITOR | Pharmaceuticals | APOLLOMICS INC. |
| Oct 26, 2023 | 2023/0338294 | NOVEL PHARMACEUTICAL FORMULATION FOR C-MET INHIBITOR | Pharmaceuticals | APOLLOMICS INC. |
| Nov 3, 2022 | 2022/0348674 | NOVEL ANTI-CD40 ANTIBODIES | Biotechnology | APOLLOMICS INC. |
| Mar 24, 2022 | 2022/0088016 | CANCER TREATMENT USING MULTI-TARGETED KINASE INHIBITOR IN COMBINATION OF PROTEIN KINASE BIOMARKERS | Analysis of biological materials | ZHEJIANG CROWNMAB BIOTECH CO. LTD. |
| Dec 2, 2021 | 2021/0371531 | ANTI PD-L1 ANTIBODIES | Pharmaceuticals | Apollomics Inc. · patent 11,827,707 granted from it |
| Jul 1, 2021 | 2021/0198363 | ANTI PD-1 ANTIBODIES | Pharmaceuticals | APOLLOMICS INC. · patent 11,560,429 granted from it |
| Dec 31, 2020 | 2020/0405719 | CANCER TREATMENT USING COMBINATION OF NEUTROPHIL MODULATOR WITH MODULATOR OF IMMUNE CHECKPOINT | Pharmaceuticals | APOLLOMICS INC. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.